Biofrontera AG reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was EUR 7.02 million compared to EUR 6.83 million a year ago. Net loss was EUR 3.14 million compared to EUR 5.1 million a year ago. Basic loss per share from continuing operations was EUR 0.05 compared to EUR 0.09 a year ago. Diluted loss per share from continuing operations was EUR 0.05.
For the nine months, sales was EUR 24.8 million compared to EUR 21.91 million a year ago. Net loss was EUR 6.29 million compared to EUR 41.85 million a year ago. Basic loss per share from continuing operations was EUR 0.1 compared to EUR 0.74 a year ago. Diluted loss per share from continuing operations was EUR 0.1.